Screener
Tarsus Pharmaceuticals, Inc. TARS Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from sale of common stock under employee stock purchase plan | 1,438 | 1,101 |
| Proceeds from exercise of stock options | 3,068 | 2,642 |
| Net cash provided by financing activities | 4,506 | 138,514 |
| Net increase in cash, cash equivalents and restricted cash | 20,393 | 1,830 |
| Cash, cash equivalents and restricted cash at beginning of period | 186,203 | 97,381 |
| Cash, cash equivalents and restricted cash at end of period | $206,596 | $99,211 |
| Supplemental Disclosures From Noncash, Investing and Financing Activities: | ||
| Interest expense paid in cash | $3,959 | $4,168 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s net change in cash?
- Tarsus Pharmaceuticals, Inc. (TARS) reported net change in cash of $102.4M in Q2 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s net change in cash?
- Over 2 years (2022 to 2024), Tarsus Pharmaceuticals, Inc.'s net change in cash has grown at a 13.1% compound annual growth rate (CAGR), from -$99.67M to -$127.57M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude